Structure-Based Drug Design (SBDD)

Structure-based drug design uses the experimentally determined or computationally predicted three-dimensional structure of a target protein, typically...

Structure-based drug design uses the experimentally determined or computationally predicted three-dimensional structure of a target protein, typically obtained by X-ray crystallography, nuclear magnetic resonance spectroscopy, or cryo-electron microscopy, to guide the design of molecules that will physically complement the target's binding site in shape, electrostatics, and hydrogen-bonding pattern. SBDD workflows typically integrate molecular docking (predicting how a candidate ligand binds within the target site), structure-based virtual screening (computationally ranking large compound libraries by predicted binding), and iterative structural refinement guided by newly solved co-crystal structures of the evolving lead series bound to the target, allowing each round of chemical modification to be directly rationalised against an accurate structural model rather than inferred indirectly.